ProofPilot, developer of the industry's first end-to-end Clinical Experience Platform (CXP), announced a strategic partnership with the Digital Medicine Society (DiMe) on April 29, 2025. This collaboration aims to advance digital health approaches in clinical trials, with a specific focus on developing tools to prevent opioid use disorder (OUD) relapse.
The partnership brings together ProofPilot's technological expertise and DiMe's mission to drive the safe, effective, and equitable use of digital approaches in healthcare. Together with other industry leaders, they will work on data-driven development of digital tools that prioritize diverse, accessible, and participant-centered study experiences.
"Partnering with DiMe aligns with our mission to improve clinical trials through digital innovation," said Chris Venezia, CEO of ProofPilot. "Together, we're bringing digital solutions to the forefront of clinical research, creating streamlined, patient-centered experiences and empowering all participants with advanced tools and support."
Addressing the Opioid Crisis Through Digital Innovation
A key focus of the collaboration will be defining and collecting physiological signals, behavior traits, and mental health characteristics to train a digital tool specifically designed to prevent OUD relapse. This initiative addresses a critical public health challenge, as opioid use disorder continues to claim thousands of lives annually in the United States.
The partnership will utilize ProofPilot's CoPilot platform to enhance study experiences, simplify data collection, and equip research sites and participants with streamlined, compliant digital solutions. This approach aims to make clinical trials more efficient and accessible while gathering crucial data to combat OUD.
Candice Taguibao, Associate Program Director for DiMe, expressed enthusiasm about the collaboration: "We greatly appreciate the level of engagement and support from the entire ProofPilot team. Their dedication to advancing digital health aligns very well with our mission. We're excited to work together to implement patient-centered approaches to clinical research and obtain insights to support the development of a digitally derived tool to help prevent relapse and reduce OUD deaths."
Expanding Digital Solutions Across Clinical Research
The ProofPilot Clinical Experience platform has been deployed across various study types, including drug and device trials, real-world evidence gathering, observational studies, and behavioral research. This versatility positions the platform to provide DiMe with the technology and engagement tools needed to make clinical trials more efficient and accessible.
The partnership reflects ProofPilot's commitment to advancing digital health solutions that meet the needs of diverse populations and deliver measurable impact for patient health. By facilitating innovative, patient-friendly digital solutions, the collaboration aims to set new standards in clinical research while addressing pressing health challenges.
Implications for Future Clinical Trials
This strategic partnership represents a significant step toward modernizing clinical trial methodologies through digital innovation. By centralizing and simplifying communication for sponsors, patients, and sites across the clinical trial experience, the ProofPilot platform addresses several persistent challenges in clinical research:
- Improving participant recruitment and retention
- Enhancing data collection efficiency and accuracy
- Creating more accessible and diverse clinical trial environments
- Developing targeted digital interventions for specific health conditions
The collaboration between ProofPilot and DiMe demonstrates how technology companies and healthcare organizations can work together to advance medical research while prioritizing patient needs and experiences. As digital approaches continue to transform healthcare delivery and research, partnerships like this will likely play an increasingly important role in addressing complex health challenges and improving patient outcomes.
